The earnings call presented a generally positive outlook with significant revenue growth and successful product launches. However, the substantial net loss and challenges in market access for SYMBRAVO present areas for concern.

Company Guidance -

Q3 2025

During the second quarter of 2025, Axsome Therapeutics reported significant metrics highlighting robust growth across its commercial and development sectors. The company achieved total revenues of $150 million, marking a substantial 72% increase year-over-year and 24% growth quarter-over-quarter. Key drivers were the impressive performances of Auvelity and Sunosi, with Auvelity generating $119.6 million in net sales, up 84% from the previous year, and Sunosi contributing $30 million, a 35% year-over-year increase. The newly launched SYMBRAVO, marketed for migraine treatment, generated net sales of $410,000 in its partial launch quarter. Axsome's gross-to-net discounts for Auvelity and Sunosi were in the mid-50% range, while SYMBRAVO's gross-to-net was in the low 80% range. The company also reported a net loss of $48 million, or $0.97 per share, including $24.6 million in stock-based compensation expenses. Axsome ended the quarter with $303 million in cash and cash equivalents, suggesting a solid financial foundation for future growth and operational expansion.

Record Revenue Growth

Axsome delivered total revenue of $150 million for the quarter, representing a 72% increase year-over-year and a 24% increase quarter-over-quarter.

Successful Product Launch

The company successfully launched SYMBRAVO, generating $410,000 in net sales within just a few weeks of launch.

Strong Performance of Existing Products

Auvelity and Sunosi showed impressive growth, with Auvelity's net product sales up 84% year-over-year and Sunosi's net product revenues up 35% year-over-year.

Pipeline Progress

Progress on late-stage development programs with multiple NDA submissions planned for the fourth quarter, including AXS-05 for Alzheimer's disease agitation and AXS-12 for narcolepsy.

Expansion in Market Access

Auvelity coverage increased to 83% of lives across all channels, with significant new covered lives added in the commercial channel.

Axsome Therapeutics (AXSM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AXSM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.83 / -	-1.34	―	―	―
Aug 04, 2025	2025 (Q2)	-1.05 / -0.97	-1.67	41.92% (+0.70)
May 05, 2025	2025 (Q1)	-1.35 / -1.22	-1.44	15.28% (+0.22)
Feb 18, 2025	2024 (Q4)	-1.00 / -1.54	-2.08	25.96% (+0.54)
Nov 12, 2024	2024 (Q3)	-1.38 / -1.34	-1.32	-1.52% (-0.02)
Aug 05, 2024	2024 (Q2)	-1.31 / -1.67	-1.54	-8.44% (-0.13)	―
May 06, 2024	2024 (Q1)	-1.21 / -1.44	-0.26	-453.85% (-1.18)	―
Feb 20, 2024	2023 (Q4)	-1.17 / -2.08	-1.41	-47.52% (-0.67)
Nov 06, 2023	2023 (Q3)	-1.20 / -1.32	-1.07	-23.36% (-0.25)	―
Aug 07, 2023	2023 (Q2)	-1.21 / -1.54	-1.06	-45.28% (-0.48)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AXSM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$103.02	$106.54	+3.42%
May 05, 2025	$112.21	$116.49	+3.81%
Feb 18, 2025	$131.15	$128.09	-2.33%
Nov 12, 2024	$90.98	$99.49	+9.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Axsome Therapeutics Inc (AXSM) report earnings?

Axsome Therapeutics Inc (AXSM) is schdueled to report earning on Nov 10, 2025, Before Open (Confirmed).

What is Axsome Therapeutics Inc (AXSM) earnings time?

Axsome Therapeutics Inc (AXSM) earnings time is at Nov 10, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AXSM EPS forecast?

AXSM EPS forecast for the fiscal quarter 2025 (Q3) is -0.83.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing